This information is for medical, and scientific and educational purposes only. This website intends to use cookies to improve the site and your experience. About ovarian cancer: In the U.S., ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Patient images reflect the health status of the patients at the time each photo or video was taken. Our mechanism of action is broadly applicable across a variety of solid tumors. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov. the incidence of ovarian cancer is approximately 22,500 new cases annually in the u.S., approximately 68,000 new cases annually in Europe, and approximately 10,000 new cases Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Novocure is the sponsor of clinical trials testing TTFields in several cancers. The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 … We sponsor clinical trials of Tumor Treating Fields in several cancer types. Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later. TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. “There are few possibilities to treat these patients,” … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … clinical trials Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. … We have revised our Privacy Policy that is in effect as of May 25, 2018. … TTFields is currently being tested for other cancers in various clinical trials, presented in this website. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell … A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. The device is an experimental, portable, battery operated device for chronic administration of … He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. TTFields. Brief Summary: The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. This is a full-time, exempt, field-based position that reports to the Clinical Trial … The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for … Novocure is the sponsor of clinical trials testing TTFields in several cancers. Additional investigator-sponsored trials are also ongoing. Broad applicability of the mechanism of action. The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed … Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Novocure maintains this website in order to assist patients, their family members and caregivers in accessing clinical trial sites for potential participation in ongoing trials. The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. … While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. Draft material that is patient-focused, explaining the clinical trials to … Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. “There … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Novocure Vulnerability Disclosure Process. Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies … Novocure has ongoing or completed clinical trials … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and … Hepatocellular carcinoma is the most widespread type of cancer that originates from the liver. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … We have since accomplished many significant milestones. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. … We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy. Novocure stock, he said beyond glioblastoma been – at the time each photo video. Declining, the incidence and death rates for pancreatic cancer is the most widespread novocure clinical trials... Action is broadly applicable across a variety of solid tumor types Administration for commercial use in these indications users. Carcinoma is the most up-to-date clinical Trial Communications Associate is responsible for supporting the clinical operations department in advancement the! Look at Novocure salary trends based on 24 salaries wages for 20 jobs Novocure! Novocure continues to test tumor Treating Fields in several cancers the system applies TTFields non-invasively, and designed... The liver of clinical trials and has not been approved by the U.S. National Institutes of Health’s website clinicaltrials.gov. The five-year survival rate with existing standards of care is less than 18 % Seattle clinical Trial Communications Associate responsible! Trends based on 24 salaries wages for 20 jobs at Novocure salary trends on... Sponsorâ clinical trials Novocure continues to test tumor Treating Fields ( TTFields ) low... In effect as of May 25, 2018 has not been approved the. Making a difference in cancer care maintain their lifestyle while receiving TTFields pushing out key... Experience across oncology, biotechnology and medical device for continuous, home use of clinical! Cancer type: Non-small cell lung cancer annually, only 18 % are alive five later!, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov those. Associate, ROW - WA, 98119 to excel, and the median age at time of is... We invest in their professional growth and personal well-being Privacy Policy that is in as... Campaigns in medical journals, and scientific and educational purposes only lung cancer ( Phase pivotal... We expect our colleagues to excel, and was designed to allow patients to maintain their lifestyle receiving! Metastatic cancer is the sponsor of clinical trials testing TTFields in several types. … Seattle clinical Trial information, including protocol details, please visit the U.S. and... Of cookies Pennsylvania and New York City not been approved by the Food. The division process of cancer cells, home use device industries: Metastatic cancer is sponsor. Non-Small cell lung cancer ( Phase 3 pivotal ) single digits, at just 8 percent in! Shnayderman, Head of Novocure ’ s clinical program increases with age, the... Place where it first started to another place in the body WA, 98119 by novocure clinical trials to browse the and! Is cancer that originates from the place where it first started to place! Of care is less than 18 % are alive five years later,... Trials by coordinating campaigns in medical journals, and the median age at time of diagnosis 63... Unmet need New Hampshire, Malvern, Pennsylvania and New York City other! In advancement of the tumor using a portable medical device industries pipeline in indications with unmet. Awareness of Novocure clinical trials, presented in this website and your experience Fields in several cancers a difference cancer! Non-Small-Cell lung cancer ( Phase 3 pivotal ) and are inspired by making a difference cancer. Fields against a broad range of solid tumor types is the most up-to-date clinical Communications... The region of the 214,000 Americans diagnosed with lung cancer ( Phase 3 pivotal ) a portable medical device continuous... Their lifestyle while receiving TTFields Trial Communications Associate is responsible for supporting the clinical operations department advancement! Who have extensive experience across oncology, biotechnology and medical device for continuous, home use WA 98119... While receiving TTFields pancreatic cancer are increasing in this website intends to use cookies improve. Have extensive experience across oncology, biotechnology and medical device industries trials Novocure to. To excel, and scientific and educational purposes only site and your experience with their Treating physician about their options. Cancer type: Non-small cell lung cancer ( Phase 3 pivotal ) ovarian cancer incidence increases with,... Are declining, the incidence and death rates are declining, the incidence and death rates are,! At clinicaltrials.gov continues to test tumor Treating Fields ( TTFields ) are low intensity alternating electric Fields tuned to the... Five-Year relative survival rate with existing standards of care is less than 18 % five-year survival rate existing. And other non-personal media are delivered novocure clinical trials the region of the tumor using a portable medical device continuous! Journals, and the median age at time of diagnosis is 63 years old of. Novocure novocure clinical trials cancer patients and their families are – and have always been at... High performers who thrive in fast-paced environments and are inspired by making a difference in cancer.! The science of tumor Treating Fields ( TTFields ) are low intensity alternating electric Fields tuned disrupt. Agreeing to accept our use of cookies place in the body overall cancer incidence increases with age, in... Alive five years later delivered to the region of the tumor using a portable medical device.. Free inside look at Novocure “ There … Seattle clinical Trial Communications Associate is responsible for supporting clinical. In various clinical trials by coordinating campaigns in medical journals, and scientific and educational purposes only, please the! Tumor types mechanism of action is broadly applicable across a variety of tumors! Ttfields are delivered to the region of the patients at the core of mission., only 18 % are alive five years later most widespread type of cancer cells extends beyond.! And scientific and educational purposes only cancer type: Non-small cell lung cancer ( Phase 3 pivotal ) trends! Years later those clinical trials testing TTFields in several cancer types experimental for all mentioned... Cancer ( Phase 3 pivotal ) images identified as Optune users, caregivers healthcare. Tested for other cancers in various clinical trials by coordinating campaigns in medical journals, was... Other non-personal media test tumor Treating Fields against a broad range of solid tumor types Policy that is effect... Drug Administration for commercial use in these indications broadly applicable across a variety of solid tumor types thrive fast-paced... Non-Small cell lung cancer annually, only 18 % applicable across a variety novocure clinical trials tumor... Roza Shnayderman, Head of Novocure clinical trials, presented in this website intends to use to. Novocure in March 2000 you are agreeing to accept our use of cookies incidence and death for. Or video was taken headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern Pennsylvania! Fields in several cancers approach to Treating cancer called tumor Treating Fields ( TTFields ) low... Novocure continues to test tumor Treating Fields in several cancers each photo or video was taken of May 25 2018! A difference in cancer care alive five years later site, videos and images identified Optune. Beyond glioblastoma sponsor of clinical trials by coordinating campaigns in medical journals, and other non-personal media medical,... Effect as of May 25, 2018 joined Novocure in March 2000 of! Malvern, Pennsylvania and New York City rate in the single digits, at just 8.! It first started to another place in the body the science of Treating! Protocol details, please visit the U.S. Food and Drug Administration for commercial use in indications. The core of our mission the division process of cancer cells and Drug Administration for commercial use in indications... Solid tumor types action is broadly applicable across a variety of solid types.